Latest AstraZeneca Stories

Syngenta Opens Unique $72 Million Advanced Crop Lab

2013-05-17 23:03:57

Syngenta unveiled its new crop research facility during a grand opening celebration today at the company’s RTP Innovation Center. The first of its kind, $72 million Advanced Crop Lab allows company researchers to simulate any agricultural climate and precisely measure plant inputs – the key to helping farmers grow more food from fewer resources. RESEARCH TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 • First of its kind research facility...

Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results

2013-05-17 04:20:46

BEIJING, May 17, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2013, before market on Tuesday, May 28, 2013. The Company will host a conference call on Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate...

A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing

2013-05-17 00:20:09

The vaccine based on Cytos' Virus-Like Particle technology may open the door to accelerated production of influenza vaccines in SingaporeSingapore and Schlieren (Zurich), Switzerland, May 17, 2013 - (ACN Newswire) - Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos'...

Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting

2013-05-15 08:30:29

BOULDER, Colo., May 15, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZeneca) at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4, 2013 in Chicago, Illinois. Both MEK inhibitors are expected to advance into Phase 3 trials in 2013: Novartis expects to evaluate MEK162 in NRAS- and BRAF-mutant melanoma...

Sinovac Appoints Ernst & Young Hua Ming Llp China as External Auditor

2013-05-15 08:29:21

BEIJING, May 15, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent public accounting firm effective from May 14, 2013 to replace Ernst & Young LLP Canada. On May 14, 2013, Ernst & Young LLP Canada notified the Company that it would not stand for re-election as the Company's registered independent public accounting firm....

Sinovac Presents at the UBS Global Healthcare Conference in May 2013

2013-05-14 08:31:46

BEIJING, May 14, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that management is scheduled to present at the UBS Global Healthcare Conference in New York City. The Sinovac management team inclusive of Nan Wang, Vice President, and Helen Yang, Director, Investor Relations and International Business Development, will present at 10:00 am ET on Monday, May 20, 2013. About Sinovac Sinovac...

Syngenta and DuPont Agree on Technology Exchange to Launch New Fungicide Solutions

2013-05-14 00:20:46

BASEL, Switzerland and WILMINGTON, Delaware, May 14, 2013 /PRNewswire/ -- Syngenta and DuPont today announced technology licensing agreements that will broaden each company's crop protection product portfolio and enable both to bring new products to market more efficiently. Syngenta has obtained a global license from DuPont to develop products containing DuPont's fungicide oxathiapiprolin. The development of this new piperidinyl thiazole isoxazoline class of fungicides...

Assessing Your Asthma is Key to Taking Control

2013-05-13 16:27:10

WILMINGTON, Del., May 13, 2013 /PRNewswire/ -- Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by taking proactive steps to gain control of their asthma and learn more about how it may be impacting their lives. To view the multimedia assets associated with this release, please click:...

Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results

2013-05-10 16:25:03

BLUE BELL, Pa., May 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2013. Total revenue was $1.5 million for the three months ended March 31, 2013, compared to $1.7 million for the same period in 2012. Total operating expenses were $8.1 million compared to $5.9 million. The net loss attributable to common stockholders was $8.8 million, or $0.06 per share, compared to $8.3 million, or $0.06 per...

Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in China

2013-05-08 08:29:35

-Medicago Ready to Collaborate with Authorities to Further Study the Potential of this Vaccine to Protect Against H7N9- QUEBEC CITY, May 8, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is...